dzd8586
Small moleculeexperimental
Clinical trial activity
9 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
7
Phase 3
1
Phase 4
0
Earliest trial started Dec 9, 2021 (NCT05176873)
Timeline
Indications
Mechanism of action
- Tyrosine-protein kinase BTKINHIBITOR
BTK inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07294365 | Phase 2 | Jan 31, 2026 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Shandong University |
| NCT07154264 | Phase 2 | Sep 22, 2025 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Sichuan University |
| NCT07139873 | Phase 3 | Sep 8, 2025 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT07059650 | Phase 1/Phase 2 (Phase 2) | Aug 19, 2025 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Sun Yat-Sen University |
| NCT06539182 | Phase 2 | Apr 29, 2024 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT06539195 | Phase 2 | Mar 13, 2024 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT05824585 | Phase 1 | Apr 30, 2023 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT05844956 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2022 | Dizal (Jiangsu) Pharmaceutical Co., Ltd. |
| NCT05176873 | Phase 1 | Dec 9, 2021 | Dizal (Jiangsu) Pharmaceutical Co., Ltd., Frontage Laboratories, Inc. |
Showing 9 of 9 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Dizal (Jiangsu) Pharmaceutical Co., Ltd. | For profit | 9 | 9 | 3 | 2021 |
| Frontage Laboratories, Inc. | For profit | 1 | 0 | 1 | 2021 |
| Shandong University | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2025 |
5 organizations
Page 1 / 1